Spectra 9 Vaccine For Dogs

Spectra 9 Canine Vaccine (DA2LPP) is for the vaccination of healthy dogs against Canine Distemper, Infectious Canine Hepatitis, Canine Adenovirus Type 2, Canine Parainfluenza, Canine Parvovirus, Leptospira Canicloa, Leptospira Icterohaemorrhagiae, Leptospira Grippotyphosa, and Leptospira Pomona. The CAV-2 fraction cross-protects against infection caused by Infectious Canine Hepatitis (CAV-1).

Suggested Vaccination Program
Puppies: Typically, puppies are vaccinated at 6 weeks of age with revaccination every 2-3 weeks until at least 16 weeks of age. Persistence of maternal origin antibodies in puppies usually determines the timing of vaccinations. All dogs over 12 weeks of age should initially receive one dose of Spectra 9 and a second dose 2 to 3 weeks later. Annual revaccination with a single 1 mL dose is recommended.

Adult dogs: Dogs over 16 weeks of age that have not been previously vaccinated should receive the initial vaccination followed with a booster 2-3 weeks later. Annual revaccination is recommended.

Dosage & Administration
Open the syringe by twisting or tapping the cap against a hard surface to break the heat weld. Aseptically rehydrate the desiccated vaccine fraction with the accompanying vial of liquid virus vaccine. Shake well and administer entire contents (1 mL) by subcutaneous (SC) injection.

Precautions
Store at 35-45° F (2-7° C). Do not freeze. Use entire contents when first rehydrated. Do not vaccinate pregnant bitches. For use in dogs only.

Packaging
A vial of desiccated vaccine containing a combination of immunogenic, attenuated stains of Canine Distemper, Canine Adenovirus Type-2,(CAV-2), Canine Parainfluenza and Canine Parvovirus Type 2b. The diluent contains killed antigens for Leptospira Canicloa, Leptospira Icterohaemorrhagiae, Leptospira Grippotyphosa and Leptospira Pomona bacterin. Needle and syringe included.

Product Benefits

• Single dose "tamper evident" sealed pack.
• Needle and syringe included.
• Independent studies have demonstrated CPV seroconversion in pups with measurable material antibody(7).
• Trials demonstrate protection against CPV-2b challenge.
• Unique killed canine adenovirus type 2 provides highly effective protection for both CAV2 and infectious canine hepatitis and eliminates risk of vaccines virus shedding.
• Ideal for cases where coronavirus is not required.
• Convenient choice of administration IM or SC.